Patient presents with [signs and symptoms, e.g., fatigue, joint pain, rash, fever].  Review of systems reveals [relevant positive and negative findings].  Patient history includes [relevant medical history, e.g., family history of autoimmune disease, recent infections, medications].  Physical examination reveals [objective findings, e.g., joint tenderness, swelling, skin changes].  Based on the clinical presentation, a positive antinuclear antibody (ANA) titer of [titer value] with a [pattern, e.g., speckled, homogenous, nucleolar] was obtained, raising suspicion for a systemic autoimmune rheumatic disease (SARD).  Differential diagnosis includes systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome, mixed connective tissue disease (MCTD), and drug-induced lupus.  Further laboratory investigations including [tests ordered, e.g., anti-dsDNA, anti-Sm, anti-Ro, anti-La, rheumatoid factor (RF), anti-CCP, complete blood count (CBC), erythrocyte sedimentation rate (ESR), complement levels] were ordered to determine the specific autoimmune etiology.  Initial management plan includes [treatment plan, e.g., patient education on autoimmune diseases, symptomatic treatment with NSAIDs for pain and inflammation, referral to rheumatology for further evaluation and management].  ICD-10 code [appropriate code, e.g., M32.00 for Systemic lupus erythematosus, unspecified] and CPT code [appropriate code for ANA testing, e.g., 86255] are documented for billing and coding purposes.  Patient will follow up in [timeframe] to discuss results and further management plans.  Prognosis depends on the underlying autoimmune condition diagnosed.